LC Paper No. CB(2)1997/17-18(01)

政府總部民政事務局

香港添馬添美道二號 政府總部西翼十二樓



GOVERNMENT SECRETARIAT HOME AFFAIRS BUREAU

12TH FLOOR, WEST WING, CENTRAL GOVERNMENT OFFICES, 2 TIM MEI AVENUE, TAMAR, HONG KONG.

本局檔號 OUR REF.

: HAB/CCF/1-55/1/4 Pt. 3

電話號碼 TEL.NO.

: 3509 7103

圖文傳真 FAXLINE

: 2147 1326

10 September 2018

Legislative Council Secretariat (Attn: Mr Dennis HO) Legislative Council Complex 1 Legislative Council Road Central, Hong Kong

Dear Mr HO,

Panel on Home Affairs Follow-up to the Meeting on 25 June 2018

At the meeting of the Panel on Home Affairs held on 25 June 2018, the Chairman requested for information on the costs for subsidising the three drugs (i.e., Nivolumab, Obinutuzumab and Nusinersen) covered by the First phase programme of medical assistance programmes and the Subsidy for eligible patients to purchase ultra-expensive drugs (including those for treating uncommon disorders) programme respectively. According to information provided by the Hospital Authority, the estimated amount of subsidies for the above-mentioned drugs in the first 12 months of introduction is as follows -

Drug

Estimated amount of subsidies

Nivolumab

\$3.11 million

Obinutuzumab

\$2.28 million

Nusinersen

\$70.3 million

Yours sincerely,

(Nick AU YEUNG)
for Secretary for Home Affairs